CAFE Comparison of Atypicals in First Episode of Psychosis
Study identifier:5077IL/0114
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison
Medical condition
schizophrenia
Phase
Phase 3
Healthy volunteers
No
Study drug
Olanzapine, risperidone
Sex
All
Actual Enrollment
-
Study type
Interventional
Age
16 Years - 40 Years
Date
Study Start Date: 01 Mar 2002
Primary Completion Date: 01 Mar 2005
Study Completion Date: 01 Mar 2005
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Jan 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
University of North Carolina
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
